Report Highlights
The global market for liquid biopsy with emphasis on cancer is expected to grow from $4.1 billion in 2026 and is projected to reach $8 billion by the end of 2031, at a compound annual growth rate (CAGR) of 14.1% during the forecast period of 2026 to 2031.
Report Includes
- 64 data tables and 58 additional tables
- An up-to-date review and analysis of the global market for liquid biopsy technologies
- Analyses of the global market trends, with sales data for 2023-2025, estimates for 2026, and projections of compound annual growth rates (CAGRs) through 2031
- Evaluation and forecast the overall market size for liquid biopsy technologies and their corresponding market share analysis by indication, technology, biomarker type, clinical application, and region
- Analysis of market opportunities with a review of Porter’s Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
- Explanation of market drivers, restraints and other forces impacting the global market
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
- Descriptive profiles of the leading global companies, including Guardant Health, Natera Inc., Exact Sciences Corp., Illumina Inc., and F. Hoffmann-La Roche Ltd.
Report Scope
The report provides an overview of the global liquid biopsy with an emphasis on cancer market and analyzes market trends. It includes global revenue ($ million), using 2025 as the base year, estimated data for 2026, and projected data from 2026 through 2031.
The report segments the market by indication, technology, biomarker type, and application. By indication, the study includes lung cancer, breast cancer, colorectal cancer, prostate cancer, and other cancers. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. Based on biomarker type, the report covers circulating nucleic acids, circulating tumor cells (CTCs), exosomes, and circulating proteins. For application, the report includes therapy guidance, therapy monitoring, early cancer screening, and recurrence monitoring. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, with a focus on key countries in these regions.
The report focuses on the key driving trends and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and highlighting the leading global liquid biopsy with an emphasis on cancer companies. It also includes a dedicated section on company profiles that covers overviews, key financials, product portfolios, and recent developments for major companies.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2025 | ||||||||||||||||
| Forecast period considered | 2026-2031 | ||||||||||||||||
| Base year market size | $3.6 Billion | ||||||||||||||||
| Market size forecast | $8 Billion | ||||||||||||||||
| Growth rate | CAGR of 14.1% for the forecast period of 2026-2031 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Indication, Technology, Biomarker Type, Application, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, South America, the Middle East and Africa | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Italy Spain, China, Japan, India, Australia, and South Korea, | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
- Rising incidence of cancers.
- Growing awareness about early cancer detection.
- Advantages of liquid biopsy over conventional tissue biopsy.
- Lower sensitivity of certain liquid biopsy procedures.
- Rising significance of precision medicine.
- Growing demand for oncology diagnostics in emerging markets.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Related Reports
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Next-generation Sequencing: Emerging Clinical Applications and Global Markets
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
Oncology Biomarkers: Global Markets
The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Intravenous (IV) Therapy and Vein Access: Global Markets
The global market for intravenous (IV) therapy and vein access is expected to grow from $49.5 billion in 2026 and is projected to reach $67.6 billion by the end of 2031, at a compound annual growth rate (CAGR) of 6.4% during the forecast period of 2026 to 2031.
Liquid Biopsy with Emphasis on Cancer: Global Markets
The global market for liquid biopsy with emphasis on cancer is expected to grow from $4.1 billion in 2026 and is projected to reach $8 billion by the end of 2031, at a compound annual growth rate (CAGR) of 14.1% during the forecast period of 2026 to 2031.
Global Pathology Services Market
The global market for pathology services was valued at $225 billion in 2025 and, is estimated to reach $307.9 billion by 2030, at a compound annual growth rate (CAGR) of 6.5% from 2025 through 2030.
Global Markets and Technologies for Electronic Health Records
The global market for electronic health records is expected to grow from $36.5 billion in 2025 and is projected to reach $52.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.4% during the forecast period of 2025 to 2030.
Global Cognitive Computing and Artificial Intelligence Systems Market in Healthcare
The global market for cognitive computing and Artificial Intelligence (AI) systems market in healthcare was valued at $11.4 billion in 2025 and, is estimated to reach $50.1 billion by 2030, at a compound annual growth rate (CAGR) of 34.4% from 2025 through 2030.
Top Trending Reports
Validation, Calibration, and Standardization in the Life Sciences Market
The global market for validation, calibration, and standardization in life sciences was valued at $2.8 billion in 2025 and is estimated to reach $3.9 billion by 2030, at a compound annual growth rate (CAGR) of 6.7% from 2025 through 2030.
Outpatient Surgical Procedures: Global Markets
The global market for outpatient surgical procedures is expected to grow from $381.9 billion in 2026 and is projected to reach $598.6 billion by the end of 2031, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2026 to 2031.
Global Markets for Fermentation Ingredients
The global market for fermentation ingredients is expected to grow from $39.8 billion in 2026 and is projected to reach $53.4 billion by the end of 2031, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2026 to 2031.
Global Enterprise Artificial Intelligence (AI) Market
This study examines the global enterprise AI market across key segments such as component, software deployment, technology, organization size, end user and geography. It focuses on commercially deployed AI software, services and hardware generating revenue across industries, including new deployments and the expansion of existing AI infrastructure. The analysis also covers emerging technologies, major market trends and challenges, the competitive landscape and profiles of leading companies. Regional market trends are assessed using 2025 as the base year, with forecasts from 2026 through 2031.
The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
The U.S. market for biodefense-related rapid pathogen identification and treatments is expected to grow from $8.4 billion in 2026 and is projected to reach $12.1 billion by the end of 2031, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2026 to 2031.
Report Highlights
The global market for liquid biopsy should grow from $2.3 billion in 2018 to reach $6.1 billion by 2023 at a compound annual growth rate (CAGR) of 21.1% for the period of 2018-2023.
Report Includes
- 27 data tables and 70 additional tables
- An overview of the global markets for liquid biopsy technologies, applications, industry subsegments
- Analyses of global market trends with data from 2017 to 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Regional dynamics of the liquid biopsy diagnostics market covering North America, Europe, APAC and rest of the world covering other emerging economies
- Discussion of major drivers, current trends and global outlook of liquid biopsy technologies, their growth potential and factors that influence the market
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Comparative study of liquid biopsy with conventional biopsy technologies and coverage of their respective biomarkers
- Comprehensive company profiles of key market players within the industry, including Apocell Inc., Becton, Dickinson and Co., Clinical Genomics Technologies, Exact Sciences Corp. and Thermo Fisher Scientific Inc.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More